title: Uraemic dyslipidaemia revisited: role of high-density lipoprotein.
abstract: Chronic kidney disease (CKD) is accompanied by strong cardiovascular risk. In a rather rigid picture of lipoprotein biology, low-density lipoprotein (LDL) is referred to as 'bad cholesterol', while high-density lipoprotein (HDL) is referred to as 'good cholesterol'. However, recent experimental evidence suggests that HDL may be rendered dysfunctional regarding its effects on the vasculature under various clinical conditions such as CKD. Indeed, HDL from the blood of CKD patients has been shown to transform into a particle which promotes endothelial dysfunction, endothelial proinflammatory activation and, thereby, sets the conditions for the development of atherosclerotic disease. Notably, pharmaceutical interventions to raise serum HDL-cholesterol levels have not been proven beneficial so far. Collectively, these findings indicate that HDL cholesterol levels do not represent a valuable marker for indicating the vascular properties of HDL.
authors: Department of Internal Medicine 4, Saarland University Hospital, Homburg/Saar, Germany.
authors: Thimoteus
authors: T
authors: Speer
authors: Stephen
authors: S
authors: Zewinger
authors: Danilo
authors: D
authors: Fliser
mesh_terms: D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D050171:Dyslipidemias / Q000209:etiology* / Q000628:therapy; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000628:therapy; D008075:Lipoproteins, HDL / Q000008:administration & dosage*; D014511:Uremia / Q000150:complications* / Q000628:therapy
chemical_list: D008075:Lipoproteins, HDL
keywords: cardiovascular disease; chronic kidney disease; endothelial dysfunction; high-density lipoprotein